NUC-3373

DRUG2 trials

Sponsors

University of Oxford, NuCana plc

Conditions

CancerColorectal CancerColorectal CarcinomaColorectal NeoplasmsColorectal TumorsNeoplasms, Colorectal

Phase 1

NUC-3373 in Advanced Solid Tumours

CompletedNCT02723240

University of OxfordCancer

Start: 2016-01-31End: 2021-02-24Updated: 2024-02-14

A Safety, Pharmacokinetic and Efficacy Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment

CompletedNCT03428958

NuCana plcColorectal Cancer, Colorectal Carcinoma, Colorectal Neoplasms +2

Start: 2018-10-05End: 2024-03-21Updated: 2025-04-23

Related Papers

A phase I open-label, dose-escalation study of NUC-3373, a targeted thymidylate synthase inhibitor, in patients with advanced cancer (NuTide:301).

2024-04-025 citations

Abstract C032: NUC-7738 in combination with pembrolizumab in patients with metastatic melanoma: Phase 2 results from the NuTide:701 study

Molecular Cancer Therapeutics2023-12-011 citations

Abstract B048: NUC-3373 in combination with irinotecan (NUFIRI) or oxaliplatin (NUFOX) and bevacizumab for second-line treatment of patients with advanced colorectal cancer (NuTide:302)

Molecular Cancer Therapeutics2023-12-011 citations

Abstract 1835: NUC-3373 targets the DNA-directed pathway more effectively than 5-FU

Cancer Research2022-06-153 citations

Abstract 1113: NUC-3373 potentiates immune-mediated cytotoxicity of CRC cells

Cancer Research2022-06-15

Abstract CT140: NUC-3373, a targeted inhibitor of thymidylate synthase, in patients with advanced colorectal cancer

Cancer Research2021-07-012 citations

A phase Ib study of NUC-3373 in combination with standard therapies in advanced/metastatic colorectal cancer (NuTide:302).

Journal of Clinical Oncology2021-01-205 citations

NuTide: 302—A phase Ib study of the ProTide NUC-3373 in combination with standard therapies in advanced colorectal cancer.

Journal of Clinical Oncology2020-02-01

Abstract C059: Inhibition of thymidylate synthase by the ProTide NUC-3373: <i>in vitro</i> analysis and clinical validation

Molecular Cancer Therapeutics2019-12-011 citations

NuTide:302: A phase Ib study to assess the safety, pharmacokinetics and clinical activity of the ProTide NUC-3373 when combined with standard agents used in colorectal cancer.

Journal of Clinical Oncology2019-01-297 citations

A phase I first-in-human, dose-escalation and expansion study to evaluate the safety and tolerability of NUC-3373 in patients with locally advanced, unresectable or metastatic solid malignancies

Annals of Oncology2018-10-012 citations

NuTide 302: A phase IB study to assess the safety, pharmacokinetics and clinical activity of NUC-3373 in combination with standard agents used in colorectal cancer treatment.

Journal of Clinical Oncology2018-05-201 citations